Abstract:Direct-to-consumer genetic testing has generated speculation about how customers will interpret results and how these interpretations will influence healthcare use and behavior; however, few empirical data on these topics exist. We conducted an online survey of DTC customers of 23andMe, deCODEme, and Navigenics to begin to address these questions. Random samples of U.S. DTC customers were invited to participate. Survey topics included demographics, perceptions of two sample DTC results, and health behaviors following DTC testing. Of 3,167 DTC customers invited, 33% (n = 1,048) completed the survey. Forty-three percent of respondents had sought additional information about a health condition tested; 28% had discussed their results with a healthcare professional; and 9% had followed up with additional lab tests. Sixteen percent of respondents had changed a medication or supplement regimen, and one-third said they were being more careful about their diet. Many of these health-related behaviors were significantly associated with responses to a question that asked how participants would perceive their colon cancer risk (as low, moderate, or high) if they received a test result showing an 11% lifetime risk, as compared to 5% risk in the general population. Respondents who would consider themselves to be at high risk for colon cancer were significantly more likely to have sought information about a disease (p = 0.03), discussed results with a physician (p = 0.05), changed their diet (p = 0.02), and started exercising more (p = 0.01). Participants' personal health contexts--including personal and family history of disease and quality of self-perceived health--were also associated with health-related behaviors after testing. Subjective interpretations of genetic risk data and personal context appear to be related to health behaviors among DTC customers. Sharing DTC test results with healthcare professionals may add perceived utility to the tests.

Regulating Direct-to-Consumer Polygenic Risk Scores

Research Progress and Challenges of Preimplantation Genetic Testing for Polygenic Diseases.

Clinical genetic counseling and translation considerations for polygenic scores in personalized risk assessments: A Practice Resource from the National Society of Genetic Counselors

Recent advances in polygenic scores: translation, equitability, methods and FAIR tools

Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores

Polygenic scores for longitudinal prediction of incident type 2 diabetes in an ancestrally and medically diverse primary care physician network: a patient cohort study

Psychosocial Effects of Receiving Genome-Wide Polygenic Risk Information Concerning Type 2 Diabetes and Coronary Heart Disease: A Randomized Controlled Trial

Polygenic risk scores: from research tools to clinical instruments

Clinical use of current polygenic risk scores may exacerbate health disparities

An analysis of direct-to-consumer genetic testing portals and their communication of health risk and test limitations

Direct-to-consumer genetic testing in the news: a descriptive analysis

Implementing polygenic risk scores in the clinic

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues

Risky Business: Risk Perception and the Use of Medical Services among Customers of DTC Personal Genetic Testing

Towards fair and clinically relevant polygenic predictions

The personal and clinical utility of polygenic risk scores

The Polygenic Score Catalog: an open database for reproducibility and systematic evaluation

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

Community-led risk analysis of direct-to-consumer whole-genome sequencing

Neither as harmful as feared by critics nor as empowering as promised by providers: risk information offered direct to consumer by personal genomics companies